Rebecca Noble/Getty Images ... from the market. "FDA is not aware of any information indicating that the known and potential benefits of the authorized COVID-19 Vaccines are outweighed by their ...

As promised, President Donald Trump hit the ground running with a swathe of executive orders issued on day one.

Rebecca Noble/Getty Images, FILE "They say it's ... to pull the vaccines from the market. "FDA is not aware of any information indicating that the known and potential benefits of the authorized ...

The federal government has allocated $1.15 billion to long-covid research without any new treatments yet brought to market.

A nasal vaccine for COVID-19—based on technology developed at Washington University in St. Louis—is poised to enter a phase 1 ...

The FDA’s action is a critical first step toward initiation of the phase 1 trial, planned for this spring. While cases of COVID-19 have fallen dramatically since the early years of the pandemic, the ...

OneBlood is the first blood center to get full FDA approval to give high-titer COVID-19 convalescent plasma to those with COVID-19 who are also immunocompromised.

One reason the FDA fell behind was the COVID-19 pandemic. It affected the agency’s ability to conduct in-person inspections (as it did for other agencies, such as the Occupational Safety and Health ...

lung diseases or COVID-19 complications. “FDA is concerned that many patients seeking cures and remedies may be misled by information about products that are illegally marketed,” the agency ...

The FDA has approved new versions of Pfizer/BioNTech's Comirnaty and Moderna's Spikevax COVID-19 vaccines that target the Omicron KP.2 strain of SARS-CoV-2 which was dominant in the US in recent ...

President Donald Trump's first week in office came with big changes to U.S. health agencies, including the pausing of all ...